Background-Data on the clinical presentation and genotype-phenotype correlation of patients with congenital long-QT syndrome (LQTS) diagnosed at perinatal through infantile period are limited. A nationwide survey was conducted to characterize how LQTS detected during those periods is different from that in childhood or adolescence. Methods and Results-Using questionnaires, 58 cases were registered from 33 institutions. Diagnosis (or suspicion) of LQTS was made during fetal life (nϭ18), the neonatal period (nϭ31, 18 of them at 0 to 2 days of life), and beyond the neonatal period (nϭ9). Clinical presentation of LQTS included sinus bradycardia (nϭ37), ventricular tachycardia/torsades de pointes (nϭ27), atrioventricular block (nϭ23), family history of LQTS (nϭ21), sudden cardiac death/aborted cardiac arrest (nϭ14), convulsion (nϭ5), syncope (nϭ5), and others. Genetic testing was available in 41 (71%) cases, and the genotype was confirmed in 29 (71%) cases, consisting of LQT1 (nϭ11), LQT2 (nϭ11), LQT3 (nϭ6), and LQT8 (nϭ1). Ventricular tachycardia/torsades de pointes and atrioventricular block were almost exclusively observed in patients with LQT2, LQT3, and LQT8, as well as in those with no known mutation. In LQT1 patients, clues to diagnosis were mostly sinus bradycardia or family history of LQTS. Sudden cardiac death/aborted cardiac arrest (nϭ14) was noted in 4 cases with no known mutations as well as in 4 genotyped cases, although the remaining 6 did not undergo genotyping. Their subsequent clinical course after aborted cardiac arrest was favorable with administration of ␤-blockers and mexiletine and with pacemaker implantation/implantable cardioverter-defibrillator. Conclusions-Patients with LQTS who showed life-threatening arrhythmias at perinatal periods were mostly those with LQT2, LQT3, or no known mutations. Independent of the genotype, aggressive intervention resulted in effective suppression of arrhythmias, with only 7 deaths recorded. (Circ Arrhythm Electrophysiol. 2010;3:10-17.)
suggest that the latter cases are at higher risk of development of life-threatening arrhythmias necessitating emergency treatment [3] [4] [5] and show higher mortality rates than the former age groups. 3, [5] [6] [7] [8] [9] [10] [11] For example, recent progress in molecular biology has clarified that LQTS partly contributes to sudden infant death syndrome (SIDS). 12, 13 Unfortunately, prenatal diagnosis of LQTS has been extremely difficult to confirm except for a limited number of cases for which prenatal gene screening 14 or fetal magnetocardiography (fMCG) [15] [16] [17] was applied.
Clinical Perspective on p 17
Thus, the clinical presentation, the genotype-phenotype correlation, and the outcome of patients with fetal, neonatal, or infantile presentation of LQTS remain to be elucidated. The purposes of this study were first, to report the findings of a nationwide survey conducted to define the clinical characteristics and the genotype-phenotype correlation, and second, to report the outcome of patients with LQTS diagnosed before birth and in the first year of life.
Methods Population
The study population included fetuses, neonates, and infants (Ͻ1 year of age) diagnosed with LQTS based on ECG findings including prolonged QTc Ͼ0.46 seconds (using Bazett formula), with or without VT/TdP, who had no structural heart disease, family history of LQTS, or had undergone genetic testing. Those with normal QTc duration and no gene mutation known to cause LQTS were excluded. Patient data were collected using questionnaires. The form was sent to those councilors of the Japanese Society of Pediatric Cardiology and Cardiac Surgery who responded to a preliminary survey that they had 1 or more cases of LQTS diagnosed during fetal, neonatal, and infantile life. The items obtained from the responders are presented in Table 1 .
The study protocol was approved by the Ethics Committee of the University Hospital of Tsukuba, and informed consent was obtained from each patient (or parents, if the patient was younger than 15 years of age) by a coordinator in charge in each institution before the patient's data were registered.
Genetic Analysis and Genotype-Phenotype Correlation
Genetic analyses were performed in 4 established laboratories in Japan. DNA was isolated from blood samples in each patient. Screening for mutations of at least 3 major genes causing LQTS (KCNQ1, KCNH2, SCN5A) was performed using polymerase chain reaction (PCR)/single-strand conformation polymorphism or denatured high-performance liquid chromatography analysis. For aberrant PCR products, DNA sequencing was conducted with a DNA sequencer (ABI 3700 and ABI 3130xl, Applied Biosystems, Foster City, Calif). For those subjects in whom genotype was confirmed and those who underwent genetic analysis but found to have no mutation, genotype-phenotype correlations (or mutation-negative phenotype correlations) with the aforementioned items (Table 1) were investigated.
Statistical Analysis
All statistical calculations were conducted using the R software. Quantitative variables (heart rate [HR] and QTc) are presented as meanϮSD and categorized variables (presence of FH, sinus bradycardia, VT/TdP, and atrioventricular block [AVB]) as proportions (percentages). One-way ANOVA was applied for comparisons of continuous variables, followed by pairwise comparisons with Bonferroni adjustment of probability values among 4 groups (LQT1, LQT2, LQT3, and mutation-negative groups). The equality of proportions for categorical variables among the 4 groups was examined by the 2 test (global test). When there was a significant difference in proportions, we performed pairwise comparisons between pairs of proportions with correction for multiple testing using Bonferroni inequality of probability values. Tests were 2-sided, and a probability value Ͻ0.05 was considered significant.
The authors had full access to the data and take responsibility for its integrity. All authors have read and agreed to the manuscript as written.
Results Population
A total of 58 cases (all Japanese; males 30, females 28) were registered from 33 institutions. Forty-one were born during the last 10 years (between 1999 and 2008), 14 between 1989 and 1998, 1 in 1986, and 2 in 1984. LQTS was diagnosed or suspected during fetal life at 18 to 40 weeks of gestation in 18 individuals, during neonatal life at 0 to 28 days in 31, and in infancy (Ͻ1 year) at 1 to 9 months in 9.
Clinical Features
For 18 fetuses with LQTS, clinical presentation (or clues to diagnosis or suspicion of LQTS) included bradycardia (15 cases), AVB (8 cases), VT/TdP (7 cases), and family history of LQTS (6 cases), including 1 family with a previous intrauterine death (items overlapped in some cases). Two fetuses were confirmed to be LQTS by fMCG, with QTc values of 570 and 680 on fMCG, and 590 and 700 on ECG soon after birth, respectively (these 2 cases have been reported previously). 16, 17 No fetal death was noted in this group.
For 31 neonates with LQTS, the most frequent feature was sinus bradycardia (17 cases), followed by VT/TdP (15 cases), positive family history of LQTS (15 cases), including 1 with previous intrauterine death and 1 with infantile death, AVB (10 cases), syncope (5 cases), convulsion (5 cases), and others (items overlapped in some cases). Among the 31 neonatal cases, 18 (70%) were diagnosed within 2 days of life, and 8 of them had some significant fetal presentation (4 bradycardia or bradyarrhythmias, 4 tachyarrhythmias, and 1 hydrops), retrospectively.
As described above, the number of patients with LQTS diagnosed during infancy beyond the neonatal period was only 9. The clinical presentation of these patients included sinus bradycardia (5 cases), sudden cardiac death (SCD)/ The ECG on diagnosis, or immediately after birth for fetal cases, showed that the HR and QTc interval (corrected using Bazett formula) ranged from 50 to 160 (102Ϯ28) bpm, and from 360 to 774 (563Ϯ70) ms, respectively.
Genotype-Phenotype Correlation
Among 41 patients who underwent genetic testing, mutations were identified in 29 (71%) cases; including KCNQ1 gene mutations (LQT1) in 11, KCNH2 mutations (LQT2) in 11, SCN5A mutations (LQT3) in 6, and CACNA1C (LQT8) in 1. Twelve patients also underwent genotyping, but no mutation was found. Table 2 lists the demographic and clinical features of these subjects (references 16, 17, and 23 reported the same cases 2, 12, and 27 in Table 2 ) and of those with no known mutations.
The remaining 17 subjects (6 fetuses, 8 neonates, 3 infants) did not undergo genetic analysis due to lack of such analysis at that time, death soon after birth, or refusal by parents. Five had SCD/ACA (Table 3) , including a 1-day-old neonate who had AVB and died at 57 days of age in 1984. This case was later assumed to be LQT8, based on characteristic phenotypes such as syndactyly. AVB and VT/TdP were observed in 7 and 5 cases, respectively, in this group.
Although HR and QTc values were not different among LQT1, LQT2, LQT3, and mutation-negative groups, the incidence of VT/TdP was higher in LQT2 and LQT3 compared with LQT1 ( Table 4 ). The incidence of AVB tended to be higher in LQT3 compared with LQT1 but statistically insignificant. On the other hand, the presence of family history of LQTS was more frequent in LQT1 than the mutation-negative group. The incidence of sinus bradycardia was comparable among the 4 groups (Table 4) . Table 3 lists cases with SCD/ACA; only 4 genetically confirmed cases were included, and 4 were mutationnegative, although the remaining 6 cases did not undergo genotyping. These individuals showed bradycardia (97Ϯ31 bpm; 10/14 showed HR Ͻ110 bpm) and markedly prolonged QTc (617Ϯ81 ms).
Treatment
With regard to the treatment of fetal VT/TdP, antiarrhythmic agents were administered transplacentally in 4 of 18 fetal cases (propranolol in 3 cases, lidocaine in 1, mexiletine in 1, flecainide in 1, and magnesium in 1), using the method described in detail in our previous report. 17 None of the 4 cases was genetically confirmed prenatally. When 2 or 3 of the following findings of sinus bradycardia, VT, and AVB were observed in a structurally normal heart, LQTS was strongly suggested, and ␤-blockers, sodium channel blockers (lidocaine, mexiletine), and magnesium (Mg) were selected as typical antiarrhythmic agents, instead of amiodarone or sotalol, which may prolong the QT interval. These drugs were used in combination until VT/TdP was controlled and proved effective in all 4 cases. However, preterm delivery was conducted in 2 cases both at 33 weeks of gestation due to recurrent VT/TdP and depression of fetal physical activity in one and to fetal hydrops and distress in the other. In the remaining 14 cases, pharmacotherapy was initiated after confirmation of the type of arrhythmias after birth. However, no fetal death was noted.
For 15 neonatal cases who presented with VT/TdP (including those who did not undergo genotyping), acute pharmacotherapy consisted of 2 or more of the following drugs: ␤-blockers, mexiletine, lidocaine, Mg, phenytoin, and others, except for 2 cases who were treated with phenytoin alone and 1 with mexiletine alone. Most of these cases were judged to respond the combination therapy. In 5 neonates in whom LQT3 was strongly suggested based on a typical ECG finding called late-appearing T wave, mexiletine was first administered but proved insufficient, and ␤-blockers were also added in all 5.
For those with LQTS presenting in infancy, 6 cases received acute pharmacotherapy (2 or all of propranolol, mexiletine, and Mg). No additional agent was administered. Thus, in all age groups, the acute therapy for VT/TdP consisted of a single drug to which 1 or more drugs was then added until the arrhythmia was controlled, independent of the genotype. Actually, the genotype was not identified during the acute phase in most cases. Furthermore, genotyping was not conducted in those 17 cases who presented before 1999.
Maintenance therapy consisted mainly of ␤-blockers (or no therapy) for LQT1 and mostly of mexiletine/␤-blockers for LQT2 and LQT3 ( Table 2) . ␤-Blockers were added in 8 LQT2 cases after confirmation of the genotype. In all 6 LQT3 cases, mexiletine was maintained (combined with ␤-blockers) from acute through chronic phase after determination of the genotype.
Nine patients underwent pacemaker implantation (PMI), 5 with ventricular pacing mode (VVI) and 1 with atrial pacing mode (AAI), from age 1 day to 8 years due to severe bradycardia caused by AVB, inducing VT/TdP. In 6 cases, VT was completely suppressed after PMI. Only 2 patients had an implantable cardioverter-defibrillator (ICD) at ages 4 (LQT3) and 25 months (mutation negative), respectively, due to recurrent VT/TdP with satisfactory results.
Outcome
During the follow-up period of 8 days to 23.5 years (median, 4.25 years), 7 SCD and 7 ACA were registered (age at SCD or ACA range, 8 days to 10 years; median, 10.5 months); 6 did not have genetic testing, whereas 4 showed no mutation. Only 4 were genetically confirmed ( Table 3) . One case was later suspected to be LQT8, based on the phenotype including syndactyly. Among the 14 SCD/ACA cases, 12 had been under pharmacotherapy, 5 with both ␤-blockers and sodium channel blockers, and 2 had had PM or ICD. Four cases developed significant neurological deficits after cardiorespiratory resuscitation.
Discussion
The noteworthy finding of the present study was that 49 of 58 cases (84%) were diagnosed at the fetal or neonatal period, although this survey covered the entire infantile period. Remarkably, two thirds of the neonatal cases were diagnosed within 2 days of life; this period should be recognized as the most vulnerable period. The number of cases diagnosed after the neonatal period was only 9. Considering that the average age at appearance of symptoms in LQT2 and LQT3 is after 4 reported 287 patients with LQTS age Ͻ21 years; their meanϮSD age at presentation was 6.8Ϯ5.6; and 9% presented with cardiac arrest, 26% with syncope, and 10% with seizures. Although 20% of their subjects were Ͻ1 month of age, they did not investigate that age group separately. In the present study, confined to the subjects age Ͻ1, clinical features were largely different; that is, the incidence of malignant arrhythmias and bradycardia was high 6, 7 whereas that of syncope and seizures was low.
Regarding genotype-phenotype correlations, Zareba et al 18 investigated child and adult LQTS and reported that LQT1 was associated with the highest risk of first cardiac event among the 3 most typical genotypes (LQT1-3). By the age of 15, syncope, ACA, or SCD was noted in 53% of their patients with LQT1 compared with 29% of LQT2 and 6% of LQT3, although cardiac events occurred in LQT3 were more lethal compared with those in LQT1 or LQT2. In contrast, the present study demonstrated that patients complicated by VT/TdP or AVB were almost exclusively those with LQT2 or LQT3 (and LQT8). LQT3 patients in the present study showed the most severe clinical course, similar to those in later-presenting LQT3. Further, patients with LQT1 mostly showed an uneventful clinical course apart from sinus bradycardia, 6 and the reason for diagnosis was bradycardia or prolonged QT interval itself on ECG identified on family screening. Another remarkable feature in our young age group was that a considerable number of patients with malignant arrhythmias were mutation-negative as far as LQT1-3 genes were typically examined. This suggests that this age group includes individuals with rare known mutations that were not examined in the present study as well as those with currently unidentifiable mutations. Data are meanϮSD or %. One-way ANOVA was used to compare mean values of HR and QTc. 2 test was used to test differences in proportions of subjects with family history, sinus bradycardia, VT/TdP, and AVB among the 4 groups. Pairwise comparisons were conducted using Bonferroni adjustment and Bonferroni inequality of P value. NS indicates not significant; Negative, gene mutation-negative group.
*No. of cases is 10 because data were not available in 1 case.
Notably, many patients in the present study showed sinus bradycardia, although HR was not significantly different among LQT1, LQT2, and LQT3. Sinus bradycardia has been considered a significant presentation of LQTS, especially in the fetal-neonatal period, 3, 19, 20 and is often a clue to the diagnosis of LQTS. The present study verified that sinus bradycardia is common among all types of LQTS in this age group, especially in fetal-neonatal periods.
Another remarkable feature of the present study was the high incidence of AVB (55% in LQT2, 83% in LQT3), compared with 5% or less in child or adult LQTS. 4, 20 It is intriguing that mutations in our LQT2 patients were almost exclusively located at the pore region of HERG gene (amino acid residues 550 through 650), 21 as mutations in that region are related to high risk for cardiac events. 21, 22 Lupoglazoff et al 6 reported similar phenotype tendency for neonates with LQTS, that AVB is associated with LQT2 and sinus bradycardia with LQT1. Most of their LQT2 cases also had a mutation in the pore region of the HERG gene, although this was not mentioned in their report. AVB in neonates with an SCN5A mutation have also been reported in single case reports. 8, 11, 23, 24 Considering the implication of sodium channel dysfunction in many other hereditary arrhythmias, 25 the association between LQT3 and AVB is an important finding. SCD/ACA was seen in 14 cases (24% of all subjects) (7 SCD, 7 ACA), even though 12 of them were under treatment with ␤-blockers, mexiletine, or both when the events occurred ( Table 3 ). The direct trigger of SCD/ACA remains to be determined, but the mean QTc interval of those patients was apparently prolonged (617Ϯ81 ms), and patients with no gene test (6 cases) were included as well, possibly making the selection of drugs inappropriate, such that only ␤-blockers were given to a possible LQT3 patient. Furthermore, 4 other cases had no known mutation on genotyping. It is possible that the cryptogenic mutations unidentifiable in the current era could be resistant to many drugs.
Therapy
Because individuals with LQT3 showed serious clinical disorders, they were treated aggressively with multiple antiarrhythmic drugs including mexiletine, ␤-blockers, lidocaine, Mg, and PM/ICD, and only 1 definite LQT3 patient showed ACA. For LQT2, malignant arrhythmias were a little more controllable with the same kind of pharmacotherapy than for LQT3. Again, only 1 definite LQT2 patient showed ACA. Thus, no death was ultimately observed in LQT2 and LQT3. This favorable clinical course might be derived from implicit strategy prevalent among pediatric cardiologists in our country that early-onset LQTS should be treated with the combination of ␤-blockers and mexiletine at the start of therapy because the genotype is not easy to confirm immediately. In other words, treatment strategies in Japan have been driven more by the clinical symptoms than by the genotype. Nevertheless, the response to the multiple antiarrhythmic pharmacotherapy and the long-term outcome presented in this study are encouraging.
It should be noted that the number of patients who underwent PMI/ICD was small in the present cohort compared with other reports. 5, 6 It is known that TdP tends to follow a prolonged R-R interval in LQT2 and LQT3, in which conduction disturbances or sinus node dysfunction are common features. 25, 26 Thus, PMI/ICD should be considered without delay even when the patient who shows drug-resistant, bradycardia-induced VT/TdP is a small baby. 27 
Study Limitations
Because of the retrospective nature of the present survey using questionnaires, the extent of clinical data that could be obtained varied among cases. Although approximate tendency in genotype-phenotype correlations for infants with LQT1, LQT2, and LQT3 was determined, most cases registered in the present study did not undergo genetic analysis for genes other than the 3 typical types. One case with LQT8 was registered in addition to LQT1-3, but no cases with the other types (LQT4 -7) were found. Also, decision of treatment strategy depended on the in-charge physician in each case without the use of a uniform protocol for VT/TdP and/or AVB, making it difficult to evaluate the effects of pharmacotherapy and to determine the event rate beyond infancy for each genotype other than the last outcome, alive or death. Therefore, we should wait for accumulation of more cases for establishment of the genotype-specific strategy.
Conclusion
Our nationwide survey indicates that early-onset malignant LQTS are mostly those with LQT2 and LQT3 among the 3 major genes, and the most vulnerable age to life-threatening arrhythmias is from 0 to 2 days of age. A combination pharmacotherapy with a ␤-blocker and mexiletine sometimes combined with Mg and PMI/ICD is recommended as the initial therapy. Prospective study of a large number of patients with LQTS diagnosed from fetal to infantile periods and further application of gene testing are needed to establish the most appropriate treatment strategies for those patients.
